Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
Year: 2024
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet HIV
Authors: Graeme Moyle, Lambert Assoumou, Nathalie de Castro, Frank A Post, Adrian Curran, Stefano Rusconi, Stephane De Wit, Christoph Stephan, François Raffi, Margaret Johnson, Mar Masia, Jaime Vera, Bryn Jones, Richard Grove, Carl Fletcher, Annie Duffy, Kellie Morris, Anton Pozniak, Graeme Moyle, Nathalie de Castro, Frank Post, Adrian Curran, Stefano Rusconi, Stephane De Wit, Christoph Stephan, François Raffi, Margaret Johnson, Mar Masia, Jaime Vera, Alan Winston, Stephen Kegg, Laura Waters, Chole Orkin, Andrew Ustianowski, Iain Reeves, Clifford Leen, Meghan Perry, Joaquin Portilla, Jose Luis Blanco, Rocio Montejaro, Pere Domingo, Jean Michel Molina, Christine Katlama, Philippe Morlat, Christopher Kenyon, Massimo Puoti, Giuliano Rizzardini, Antonella Castagna, Francesco Castelli, Andrea Giacomelli, Jürgen Rockstroh, Stefan Esser, Christian Hoffmann, Patrick Mallon
Institutions: Chelsea and Westminster Hospital, Inserm, Sorbonne Université, Institut Pierre Louis d‘Épidémiologie et de Santé Publique, Hôpital Saint-Louis, King's College Hospital NHS Foundation Trust, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, University of Milan, Aziende Socio Sanitarie Territoriale Ovest Milanese, Centre Hospitalier Universitaire de Saint-Pierre, Goethe University Frankfurt, University Hospital Frankfurt, Centre Hospitalier Universitaire de Nantes, Centre d'Investigation Clinique de Nantes, Nantes Université, The Royal Free Hospital, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red, Hospital General Universitario de Elche, Centro de Investigación Biomédica en Red Enfermedades Infecciosas, Brighton and Sussex Medical School, Brighton and Sussex University Hospitals NHS Trust, ViiV Healthcare (United Kingdom), GlaxoSmithKline (United Kingdom), GlaxoSmithKline Research & Development Limited (United Kingdom), London School of Hygiene & Tropical Medicine
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: ViiV Healthcare
OpenAlex ID: W4392180047
